摘要
目的 对比分析非小细胞肺癌晚期患者单给予TP化疗效果、TP化疗+贝伐珠单抗效果差异.方法 前瞻性选取2020年6月至2023年12月在延安市人民医院接受治疗的晚期非小细胞肺癌患者120例作为研究对象,按照随机数字表法将其分为对照组、观察组,每组各60例.对照组给予TP化疗,观察组在TP化疗基础上联合贝伐珠单抗.比较两组治疗3个月后的临床疗效,治疗前、治疗3个月后的肿瘤标志物[癌胚抗原、糖类抗原(CA)125、CA199、甲胎蛋白]、免疫功能[免疫球蛋白(Ig)A、IgM、IgG]水平以及毒副反应发生率的差异.结果 治疗3个月后,观察组总有效率为73.33％,显著高于对照组(55.00％),差异有统计学意义(P＜0.05).治疗3个月后,两组癌胚抗原、CA125、CA199、甲胎蛋白水平均较治疗前降低,且观察组的癌胚抗原、CA125、CA199、甲胎蛋白水平分别为(3.36±0.50)ng/mL、(30.64±4.80)U/mL、(58.91±6.04)U/mL、(8.19±1.82)IU/mL,均低于对照组[(5.46±1.03)ng/mL、(38.05±5.79)U/mL、(65.80±7.82)U/mL、(10.20±2.00)IU/mL],差异均有统计学意义(P＜0.05).治疗 3 个月后,两组 I gA、IgM、IgG 水平均较治疗前降低,但观察组IgA、IgM、IgG水平分别为(1.60±0.32)、(2.70±0.44)、(11.48±1.62)g/L,均明显高于对照组[(0.94±0.49)、(1.48±0.51)、(7.95±1.53)g/L],差异均有统计学意义(P＜0.05).观察组的总毒副反应发生率为31.67％,明显低于对照组(50.00％),差异有统计学意义(P＜0.05).结论 贝伐珠单抗、TP化疗两种方案联合使用可调节晚期非小细胞肺癌患者的肿瘤标志物水平,改善疗效,还能降低对免疫功能的影响,抑制毒副反应发生概率,值得推广.
Abstract
Objective To compare and analyze the differences in the efficacy of TP chemotherapy alone and TP chemotherapy plus bev-acizumab in advanced non-small cell lung cancer patients.Methods A total of 120 patients with advanced non-small cell lung cancer who were treated in Yan'an People's Hospital from June 2020 to December 2023 were prospectively selected as the research objects.According to the random number table method,they were divided into the control group and the observation group,with 60 cases in each group.The control group received TP chemotherapy,while the observation group received a combination of TP chemotherapy and bevacizumab.The clinical efficacy after 3 months of treatment,the levels of tumor markers[carcinoembryonic antigen,carbohydrate antigen(CA)125,CA199,alpha-fetoprotein],im-mune function[immunoglobulin(Ig)A,IgM,IgG]before and after 3 months of treatment and the incidence of toxic and side effects were com-pared between the two groups.Results After 3 months of treatment,the total effective rate of the observation group was 73.33％,which was sig-nificantly higher than that of the control group(55.00％),and the difference was statistically significant(P＜0.05).After 3 months of treat-ment,the levels of carcinoembryonic antigen,CA125,CA199 and alpha-fetoprotein in the two groups were lower than those before treatment,and the levels of carcinoembryonic antigen,CA125,CA199 and alpha-fetoprotein in the observation group were(3.36±0.50)ng/mL,(30.64±4.80)U/mL,(58.91±6.04)U/mL,(8.19±1.82)IU/mL,respectively,which were lower than those in the control group[(5.46±1.03)ng/mL,(38.05±5.79)U/mL,(65.80±7.82)U/mL,(10.20±2.00)IU/mL],the differences were statistically significant(P＜0.05).After 3 months of treatment,the levels of IgA,IgM and IgG in the two groups were lower than those before treatment,but the levels of IgA,IgM and IgG in the observation group were(1.60±0.32),(2.70±0.44)and(11.48±1.62)g/L,respectively,which were significantly higher than those in the control group[(0.94±0.49),(1.48±0.51),(7.95±1.53)g/L],the differences were statistically significant(P＜0.05).The incidence of total toxic and side effects in the observation group was 31.67％,which was significantly lower than that in the control group(50.00％),and the difference was statistically significant(P＜0.05).Conclusion The combination therapy of bevacizumab and TP chemo-therapy can not only regulate tumor marker levels and improve efficacy in the treatment of advanced non-small cell lung cancer,but also reduce the impact on immune function and inhibit the probability of toxic side effects,which is worthy of promotion.
NETL
NSTL
万方数据